Cardiac safety and efficacy for patients with early-stage breast cancer treated with pegylated liposomal doxorubicin (PLD) or doxorubicin.

被引:0
|
作者
Tang, Lichen
He, Min
Wu, Jiong
Wang, Zhonghua
Liu, Guangyu
Yu, Keda
Geng, Cuizhi
Fan, Zhimin
Ling, Rui
Qiao, Guangdong
Cai, Li
Luo, Ting
Jin, Feng
Wang, Haibo
Zhang, Anqin
Zhang, Hongwei
Zeng, Xiaohua
Wang, Xiaojia
Jiang, Ming
Shao Zhimin
机构
[1] Fudan Univ, Dept Breast Surg, Shanghai Canc Ctr, Shanghai, Peoples R China
[2] Fudan Univ, Shanghai Canc Ctr, Dept Oncol, Shanghai Med Coll, Shanghai, Peoples R China
[3] Fudan Univ, Dept Breast Surg, Shanghai Canc Ctr, Shanghai Med Coll, Shanghai, Peoples R China
[4] Fudan Univ, Shanghai Med Coll, Dept Oncol, Key Lab Breast Canc Shanghai, Shanghai, Peoples R China
[5] Fourth Hosp Hebei Med Univ, Shijiazhuang, Peoples R China
[6] First Hosp Jilin Univ, Dept Breast Surg, Changchun, Peoples R China
[7] Air Force Mil Med Univ, Xijing Hosp, Xian, Peoples R China
[8] Yuhuangding Hosp Yantai, Yantai, Peoples R China
[9] Harbin Med Univ, Canc Hosp, Harbin, Peoples R China
[10] Sichuan Univ, Breast Dis Ctr, West China Hosp, Chengdu, Peoples R China
[11] First Hosp China Med Univ, Dept Breast Surg, Shenyang, Peoples R China
[12] Qingdao Univ, Affiliated Hosp, Qingdao, Peoples R China
[13] Guangdong Women & Children Hosp, Guangzhou, Peoples R China
[14] Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China
[15] Chongqing Univ, Dept Breast Canc Ctr, Canc Hosp, Chongqing, Peoples R China
[16] Univ Chinese Acad Sci, Zhejiang Canc Hosp, Inst Canc & Basic Med, Chinese Acad Sci,Dept Med Oncol,Canc Hosp, Hangzhou, Peoples R China
[17] Cent Hosp Wuhan, Wuhan, Peoples R China
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
550
引用
收藏
页数:1
相关论文
共 50 条
  • [1] Pegylated liposomal doxorubicin for adjuvant treatment of breast cancer in patients refusing therapy with conventional doxorubicin.
    Manenfe, P.
    Vicario, G.
    Sgarbossa, G.
    Girardi, F.
    Bortolin, M.
    Scelzi, E.
    Sartor, L.
    Vultaggio, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [2] LONG TERM CARDIAC SAFETY OF PEGYLATED LIPOSOMAL DOXORUBICIN (PLD) IN PATIENTS WITH BREAST CANCER (BC) PREVIOUSLY TREATED WITH CONVENTIONAL ANTHRACYCLINES
    Llombart, A.
    Mayordomo, J. I.
    Anton, A.
    Santaballa, A.
    Ruiz, A.
    Rodriguez-Lescure, A.
    ANNALS OF ONCOLOGY, 2010, 21 : 120 - 120
  • [3] Efficacy and safety of generic pegylated liposomal doxorubicin (PLD) in relapsed ovarian cancer
    Ghosh, I.
    Dwary, A.
    Dabkara, D.
    Bhaumik, J.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S731 - S731
  • [4] Cardiac Safety of Pegylated Liposomal Doxorubicin After Conventional Doxorubicin Exposure in Patients With Sarcoma and Breast Cancer
    Alhaja, Maher
    Chen, Sherry
    Chin, Alan C.
    Schulte, Brian
    Legasto, Carlo S.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (09)
  • [5] Safety Aspects of Pegylated Liposomal Doxorubicin in Patients with Cancer
    David S. Alberts
    Dava J. Garcia
    Drugs, 1997, 54 : 30 - 35
  • [6] Safety aspects of pegylated liposomal doxorubicin in patients with cancer
    Alberts, DS
    Garcia, DJ
    DRUGS, 1997, 54 (Suppl 4) : 30 - 35
  • [7] A metanalysis of the efficacy and safety of pegylated liposomal doxorubicin
    Castellanos-Toledo, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [8] Selective cardiac surveillance in patients with gynecologic cancer undergoing treatment with pegylated liposomal doxorubicin (PLD)
    Kushnir, C. L.
    Angarita, A. M.
    Havrilesky, L. J.
    Thompson, S.
    Spahlinger, D.
    Sinno, A. K.
    Tanner, E. J.
    Secord, A. A.
    Roche, K. L.
    Stone, R. L.
    Fader, A. N.
    GYNECOLOGIC ONCOLOGY, 2015, 137 (03) : 503 - 507
  • [9] Incidence of interstitial pneumonitis in breast cancer patients treated with pegylated liposomal doxorubicin
    Liwei Meng
    Liming Huang
    Yingchun Xu
    Wei Zhang
    Cancer Chemotherapy and Pharmacology, 2020, 85 : 3 - 7
  • [10] Incidence of interstitial pneumonitis in breast cancer patients treated with pegylated liposomal doxorubicin
    Meng, Liwei
    Huang, Liming
    Xu, Yingchun
    Zhang, Wei
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 85 (01) : 3 - 7